Drug intelligence / Profile preview

CKD-349

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CKD-349 is an investigational small molecule drug developed by Chong Kun Dang Pharmaceutical Corp. for the treatment of chronic heart failure. It has also been studied in the context of chronic kidney disease, but its primary indication is chronic heart failure. The precise mechanism of action for CKD-349 has not been disclosed or remains unknown as of the latest available data. The drug has completed Phase 1 clinical trials evaluating its safety and pharmacokinetics in healthy adult volunteers, with oral administration as the tested route[1][2][3].

Other names: CKD-349CKD349CKD 349

Beyond the preview

Go deeper on CKD-349.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-349.

Explore the full profile